Schrödinger Secures BMS as Strategic Bunsen Partner, Validating Agentic AI Offering

What happened

Schrödinger announced a strategic collaboration and software agreement with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, inside BMS’s research organization. The deal marks an early, concrete win for the Bunsen platform, which management had targeted for a summer 2026 launch and identified as a key driver of throughput-based licensing expansion. While financial terms were not disclosed, the partnership with a top-20 pharma customer provides real-world validation of Bunsen’s ability to embed in large-scale discovery workflows. This development aligns directly with the bull case, which hinges on Bunsen increasing seat and usage expansion among top pharma clients, but it does not alter the near-term challenge of a hosted-revenue trough that has pressured software margins and deferred revenue. Investors now need to see whether the BMS engagement translates into measurable ACV growth and helps stabilize the declining deferred revenue balance.

Implication

The BMS collaboration offers tangible evidence that Bunsen is gaining traction in top pharma, supporting the thesis that agentic AI can drive software expansion. However, without disclosed economics or multi-year commitments, the near-term financial impact remains unclear, and the hosted transition’s revenue headwinds persist. Investors should monitor whether this win catalyzes additional deals and lifts ACV growth above the 10–15% guided range, which would meaningfully de-risk the thesis.

Thesis delta

The BMS deal provides credible, early-stage validation that Bunsen’s agentic AI co-scientist is being adopted by a major pharma, directly supporting the bull case driver of throughput-based licensing expansion. However, the lack of disclosed financial terms means it does not yet alter the base-case valuation or offset the ongoing hosted-transition revenue drag. The thesis gains incremental confidence, but confirmation requires sustained ACV acceleration and deferred revenue stabilization.